QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.015933v1 69/1/130    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leontiou, C. Articles by Austin, C. A. Search for Related Content PubMed PubMed Citation Articles by Leontiou, C. Articles by Austin, C. A.

Mutation P732L in Human DNA Topoisomerase II Abolishes DNA Cleavage in the Presence of Calcium and Confers Drug Resistance

Institute for Cell and Molecular Biosciences, The Medical School, University of Newcastle upon Tyne, United Kingdom

The anti cancer drug methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide (mAMSA) targets human DNA topoisomerase II. We report here the first selection with mAMSA of resistant human topoisomerase II. Random mutagenesis of human DNA topoisomerase II cDNA, followed by selection in yeast for resistance to mAMSA, identified P732L. This mutant was 10-fold less sensitive to mAMSA and cross-resistant to other chemotherapeutic agents such as etoposide, ellipticine, methyl N-(4'-(9-acridinylamino)-2-methoxy-phenyl) carbamate hydrochloride (mAMCA), methyl N-(4'-(9-acridinylamino)-phenyl) carbamate hydrochloride (AMCA), and doxorubicin. P732L is functional but has reduced strand passage activities and altered DNA binding compared with the wild-type protein. It has drastically altered cleavage properties compared with the wild-type enzyme. It cleaved a 40-base pair (bp) DNA substrate in the presence of magnesium but at positions different from that of the wild-type protein. More striking is that P732L was unable to cleave the 40-bp DNA substrate, a 500-bp linear substrate, or a 4.3-kilobase supercoiled substrate in the presence of calcium ions. This is the first report of a topoisomerase II mutation abolishing the ability of calcium to support DNA cleavage. This provides evidence for metal ion requirement for the phosphoryltransfer reaction of topoisomerase II and a possible mechanism for drug resistance.

Address correspondence to: Professor Caroline A. Austin, Lab 3011, Institute for Cell and Molecular Bioscience, The Medical School, University of Newcastle, Newcastle upon Tyne, NE2 4HH, UK. E-mail: caroline.austin{at}ncl.ac.uk

This article has been cited by other articles:

				J. E. Deweese and N. Osheroff The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing Nucleic Acids Res., February 1, 2009; 37(3): 738 - 748. [Abstract] [Full Text] [PDF]

				C. Leontiou, G. P. Watters, K. L. Gilroy, P. Heslop, I. G. Cowell, K. Craig, R. N. Lightowlers, J. H. Lakey, and C. A. Austin Differential Selection of Acridine Resistance Mutations in Human DNA Topoisomerase IIbeta Is Dependent on the Acridine Structure Mol. Pharmacol., April 1, 2007; 71(4): 1006 - 1014. [Abstract] [Full Text] [PDF]

				B.-G. Ju, V. V. Lunyak, V. Perissi, I. Garcia-Bassets, D. W. Rose, C. K. Glass, and M. G. Rosenfeld A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science, June 23, 2006; 312(5781): 1798 - 1802. [Abstract] [Full Text] [PDF]